ArticleVirology journal2025
Evaluation of the duration of new nasal drug interferon α-2b activity in an experimental model system.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Genetic Engineering to Preclinical Safety: A Study on Recombinant Human Interferons.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
this study aimedTo develop an adequate system for assessing the duration of IFN antiviral activity in the nasal cavity of animals and to study the antiviral activity of a new IFN drug in the form of a gel in comparison with the known spray form.
methodsTo assess the duration of the specific activity of IFN, the drugs were administered into the nasal cavity of experimental rats. One, 3, and 4 h after administration, the nasal cavities of the rats were washed out, and the antiviral activity of washed from the nasal cavity (WNC) was analyzed in vitro.
resultsDeveloped an algorithm to assess the duration of antiviral activity of nasal preparations using a sensitive in vitro test system, in which the analysis of the antiviral activity of WNC made it possible to detect antiviral activity after the administration of nasal forms of IFN-a new variant in the form of a gel in comparison with the IFN spray. It was established that 1 h after the intranasal administration of IFN, the same antiviral activity and IFN concentration is: 266.8 ± 14.0 IU/ml for IFN/spray and 260.2 ± 20.9 IU/ ml for IFN/gel. Three hours after the drugs are administered, their activity decreases but remains at a sufficiently high level: 121.4 ± 5.4 IU/ml for IFN/spray and 88.3 ± 6.2 IU/ml for IFN/gel. Four hours after IFN administration, the concentration of IFN/gel was significantly greater than that of IFN/spray: 39.4 ± 4.9 IU/ml and 10.6 ± 1.0 IU/ml, respectively.
conclusionThe developed system for evaluating the antiviral activity of nasal preparations allows the study of the duration of the local antiviral effect of drugs. The antiviral activity of the IFN nasal preparations persisted for 4 h after their intranasal administration: the concentration of IFN in gel form on the walls of the nasal cavity was significantly greater than that of the IFN spray.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.